Cell Therapeutics (CTIC) Posts Q3 Loss of 16c/Share; Resubmits Pixantrone NDA to FDA
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq set for higher open as oil prices extend declines, midterm results awaited
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Price: $9.09 --0%
Financial Fact:
Basic and diluted net loss per common share: -0.1
Today's EPS Names:
INM, TRI, CRVL, More
Financial Fact:
Basic and diluted net loss per common share: -0.1
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Cell Therapeutics Inc. (NASDAQ: CTIC) reported Q3 loss of ($0.16), $0.07 worse than the analyst estimate of ($0.09).
Cell Therapeutics also resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma for patients who have failed two or more prior lines of therapy.
Cell Therapeutics also resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma for patients who have failed two or more prior lines of therapy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Versant Corp. (VSNT) Reports Q3 EPS of $0.34 ; Offers Guidance
- Knife River Corporation (KNF) Misses Q3 EPS by 78c ; Offers Guidance
Create E-mail Alert Related Categories
Commodities, Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
